229 related articles for article (PubMed ID: 37789040)
21. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2024 Jan; 42(3):662-670. PubMed ID: 38129286
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
[TBL] [Abstract][Full Text] [Related]
27. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
[TBL] [Abstract][Full Text] [Related]
28. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Masuda T; Mori M
Vaccine; 2024 Feb; 42(6):1319-1325. PubMed ID: 38310018
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Costa Clemens SA; Marchevsky N; Kelly S; Felle S; Eldawi A; Rajasingam R; Mahmud R; Lambe T; Voysey M; Gonzalez I; Milan EP; Justino MC; Bibi S; Aley P; Clemens R; Pollard AJ
Hum Vaccin Immunother; 2023 Aug; 19(2):2233400. PubMed ID: 37438960
[TBL] [Abstract][Full Text] [Related]
30. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
31. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
32. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
33. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
[TBL] [Abstract][Full Text] [Related]
34. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
Batmunkh T; Moore KA; Thomson H; Altangerel B; Amraa O; Avaa N; Batbayar L; Batsukh K; Bright K; Burentogtokh T; Ha Do LA; Dorj G; Hart JD; Javkhlantugs K; Jigjidsuren S; Justice F; Li S; Licciardi PV; Mashbaatar K; Mazarakis N; Neal EFG; Nguyen CD; Ochirbat B; Tsolmon B; Tuya A; Surenjav U; von Mollendorf C; Mulholland K
Lancet Reg Health West Pac; 2024 Jan; 42():100953. PubMed ID: 38357398
[TBL] [Abstract][Full Text] [Related]
36. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
Saraf A; Gurjar R; Kaviraj S; Kulkarni A; Kumar D; Kulkarni R; Virkar R; Krishnan J; Yadav A; Baranwal E; Singh A; Raghuwanshi A; Agarwal P; Savergave L; Singh S;
Nat Med; 2024 May; 30(5):1363-1372. PubMed ID: 38637636
[TBL] [Abstract][Full Text] [Related]
37. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B;
EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
J Infect Dis; 2023 Nov; ():. PubMed ID: 37970668
[TBL] [Abstract][Full Text] [Related]
40. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
